Patents Assigned to Medivation Technologies, Inc.
-
Publication number: 20210317140Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.Type: ApplicationFiled: October 17, 2014Publication date: October 14, 2021Applicant: Medivation Technologies, Inc.Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahman PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
-
Patent number: 9670172Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.Type: GrantFiled: August 28, 2014Date of Patent: June 6, 2017Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma
-
Publication number: 20170137410Abstract: Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl-pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: ApplicationFiled: June 26, 2015Publication date: May 18, 2017Applicant: Medivation Technologies, IncInventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI, Anil Kumar AGARWAL
-
Publication number: 20170119907Abstract: This disclosure describes compositions and methods for delivering and localizing therapeutic agents to therapeutic targets. This disclosure also provides multivalent forms of cationic dyes (“cationic dye multimers”) and methods by which these compounds can be used to treat joint injuries.Type: ApplicationFiled: January 28, 2015Publication date: May 4, 2017Applicant: Medivation Technologies, Inc.Inventors: David Hung, Sarvajit Chakravarty, Roopa Rai, Sebastian Bernales, Balaji Dashrath Sathe, Gonzalo Ureta, Emma McCullagh
-
Patent number: 9580425Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: September 12, 2014Date of Patent: February 28, 2017Assignee: Medivation Technologies, Inc.Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty
-
Patent number: 9550782Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.Type: GrantFiled: March 7, 2013Date of Patent: January 24, 2017Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
-
Patent number: 9527854Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: GrantFiled: March 6, 2015Date of Patent: December 27, 2016Assignee: Medivation Technologies, Inc.Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
-
Patent number: 9499519Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: GrantFiled: December 26, 2013Date of Patent: November 22, 2016Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green, Amantullah Ansari
-
Patent number: 9481676Abstract: This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.Type: GrantFiled: October 8, 2013Date of Patent: November 1, 2016Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: David T. Hung, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
-
Patent number: 9469641Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds of formula (F) are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: November 16, 2012Date of Patent: October 18, 2016Assignee: Medivation Technologies, Inc.Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Sundeep Dugar
-
Patent number: 9458155Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: November 3, 2014Date of Patent: October 4, 2016Assignee: MEDIVATION TECHNOLOGIES, INCInventors: David T. Hung, Andrew A. Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
-
Publication number: 20160272645Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.Type: ApplicationFiled: October 17, 2014Publication date: September 22, 2016Applicant: Medivation Technologies, Inc.Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahmam PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
-
Patent number: 9434747Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.Type: GrantFiled: February 17, 2012Date of Patent: September 6, 2016Assignee: Medivation Technologies, Inc.Inventors: Andrew Asher Protter, Sarvajit Chakravarty
-
Patent number: 9433626Abstract: This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: April 30, 2015Date of Patent: September 6, 2016Assignee: Medivation Technologies, Inc.Inventors: Sarvajit Chakravarty, Barry Patrick Hart, Rajendra Parasmal Jain
-
Patent number: 9422267Abstract: The present invention provides fused pyrimidine compounds of the general Formula (I): or a salt thereof, wherein the variables are as defined in the specification. Fused pyrimidine compounds of the general Formula (I) are provided as kinase inhibitors, such as multi-kinase inhibitors. In one aspect, fused pyrimidine compounds of the general Formula (I) are provided as IGF-IR inhibitors. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compounds of the general Formula (I) and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound of the general Formula (I) or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: GrantFiled: December 26, 2013Date of Patent: August 23, 2016Assignee: Medivation Technologies, Inc.Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green
-
Patent number: 9409910Abstract: This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.Type: GrantFiled: March 8, 2013Date of Patent: August 9, 2016Assignee: Medivation Technologies, Inc.Inventors: David T. Hung, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
-
Publication number: 20160068513Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: ApplicationFiled: December 26, 2013Publication date: March 10, 2016Applicant: MEDIVATION TECHNOLOGIES, INC.Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI
-
Patent number: 9271971Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: June 12, 2015Date of Patent: March 1, 2016Assignee: Medivation Technologies, Inc.Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty
-
Patent number: 9260429Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds having the structures are described, as are pharmaceutical-compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: December 21, 2012Date of Patent: February 16, 2016Assignee: Medivation Technologies, Inc.Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Sundeep Dugar
-
Patent number: 9255094Abstract: Provided are new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Also provided are pyrido[4,3-b]indoles, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: April 29, 2010Date of Patent: February 9, 2016Assignee: Medivation Technologies, Inc.Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty